ImmunotherapiesCongress.com

August 13-15, 2013 • Hilton Boston Back Bay Hotel • Boston, MA Preliminary Agenda

Register by May 17 and Save up to $300!

Organized by:Cambridge Healthtech Institute

Inaugural

Immunomodulatory Antibodies for Cancer August 14-15

Inaugural

Emerging Cancer Immunotherapies and VaccinesAugust 13-14

Sessions Include:

• Cancer Biology and Biomarkers

• Emerging Cancer Immunotherapies & Vaccines

• Clinical Development of Immunomodulatory Antibodies

• Bispecific Immunomodulatory Antibodies

Keynote Presentation:

The Promise of T-Cell EngineeringMichel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center

Immune Monitoring on Pre-surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4 Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology,University of Texas MD Anderson Cancer Center

Pre-Conference Short Course:

Immunotherapy Strategies for Melanoma

ImmunoThe

Congressherapies Immune System Modulation

for Novel Cancer Treatments

ImmunotherapiesCongress.com

Co-Located Event Eighth Annual

Novel Vaccines: Innovations & AdjuvantsTo Advance the Science of Vaccines

2ImmunotherapiesCongress.com

Pre-Conference Short Course * Monday, August 12 • 2:00-5:00

Immunotherapy Strategies for Melanoma As understandings of cancer biology, human genetics and immunology evolve, new strategies for treatment of melanomas with a combination of targeted therapeutics and immunotherapies are progressing at a rapid pace. This short course will survey the most promising emerging targets for cancer therapeutics and explore how these will integrate with cancer vaccines and other immunotherapies for maximum clinical effect.

Instructors TBA

Topics to be discussed:

• New advances in knowledge of melanoma biology

• New targets (PD-1, PRL-1, CTLA-4, OX40, CD40, GITR, 4-1BB)

• Combining targeted agents and immunotherapies

• Identification of immunotherapy biomarkers to improve therapeutic efficacy

*Separate registration required

Conference Hotel:

Hilton Boston Back Bay Hotel40 Dalton StreetBoston, MA 02115Phone: 617-236-1100

Discounted Room Rate: $195 s/dDiscounted Room Rate Cut-off Date: July 15, 2013Please visit our conference website to make your reservations online or call the hotel directly to reserve your sleeping accommodations. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

HOTEL & TRAVEL INFORMATION

Flight Discounts:To receive a 5% or greater discount on all American Airline flights please use one of the following methods:

• Call 1-800-433-1790 use Conference code (8283BJ) • Go online www.aa.com enter Conference code (8283BJ) in promotion

discount box• Contact Rona Meizler, Great International Travel 1-617-559-3735

Car Rental Discounts: Special discount rentals have been established with Hertz for this conference. Please use one of the following methods:

• Call HERTZ, 800-654-3131 use our Hertz Convention Number (CV): 04KL0002• Go online www.hertz.com use our Hertz Convention Number (CV): 04KL0002

Sponsoring Pubs

3 ImmunotherapiesCongress.com

KEyNoTE PRESENTATIoN: The Promise of T-Cell EngineeringMichel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center

Cancer Biology and Biomarkers

Advances in Biomarker Validation and Trial Design for Antitumor ImmunotherapySusan R. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center

Emerging Cancer Immunotherapies

Identifying New Cancer Immunotherapy Targets for T CellsRobert Holt, Ph.D., Head, Sequencing, Michael Smith Genome Sciences Center, BC Cancer Agency, Canada

An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 Trans-Presentation at the Tumor SiteDafne Müller, Ph.D., Researcher, Institute of Cell Biology and Immunology, University of Stuttgart, Germany

TIM (T Cell Immunoglobulin and Mucin)-3 as a Potential Target for Cancer ImmunotherapyAna Carrizosa Anderson, Ph.D., Assistant Professor, Harvard Medical School

Allovectin: In vivo Studies and Potential Synergy with other Advanced Melanoma ImmunotherapeuticsJohn Doukas, Ph.D., Senior Director, Preclinical Safety and Efficacy, Vical, Inc.

Clinical Update of IL2 Adjunctive Cotherapy for Suppression of Solid Tumors with Designer T CellsRichard P. Junghans, M.D., Professor, Department of Medicine, Boston University; School of Medicine, Roger Williams Medical Center

Emerging Cancer Vaccines

Retrospective Biomarker Studies for ProvengeJames Trager, Ph.D., Vice President, Research, Dendreon

Partnering Therapeutic Vaccines with Large PharmaKevin Heller, Global Lead, Oncology; Search, Evaluation and Diligence, Bristol-Myers Squibb

Clinical Results of JX594: oncolytic Tumor Viruses as a Strategy for Cancer VaccinesAnne Moon, Ph.D., Vice President, Product Development, Jennerex

Clinical Update on PRoSTVAC, a Therapeutic Vaccine Candidate for Advanced Prostate CancerAlain Delcayre, Ph.D., Vice President, R&D, BN Immunotherapeutics

Inaugural

Emerging Cancer Immunotherapies and VaccinesNext-Generation Targets and Strategies

August 13-14

Using lessons learned from early cancer vaccines and immunotherapeutics, a new wave of programs are underway that promise improved efficacy and safety over a wider range of cancers. Emerging Cancer Immunotherapies and Vaccines will examine new targets and strategies in this space, along with important studies in preclinical development associated with developing these programs into successful drug products. Speakers will offer approaches to resolve the most challenging steps in the transition of these programs from research into clinical development.

4ImmunotherapiesCongress.com

The recent approval of BMS’s Yervoy (ipilumumab) and a succession of related programs advancing through clinical trials has generated increased interest in the development of antibody-based immunomodulators for cancer. Immunomodulatory Therapeutic Antibodies for Cancer will provide updates of clinical stage programs, and examine how these novel therapeutics influence trial design and the selection of clinical endpoints. Strategies for immune modulation that are most appropriate for targeting with antibodies will be considered, along with where combination regimens and new therapeutic formats can be effectively applied.

Inaugural

Immunomodulatory Antibodies for CancerClinical Progress and Challenges in Drug Product Development

August 14-15

KEyNoTE PRESENTATIoN: Immune Monitoring on Pre-surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4 Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center

Immune Checkpoint Blockades

Clinical Update of MK-3475: A Humanized IgG4 Anti-PD-1 Monoclonal Antibody for Progressive, Locally Advanced, or Metastatic Carcinoma, Melanoma, or NSCLCOmid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute

Anti-PD-1 Antibody Therapy for B-Cell LymphomaSattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

AMP-224, A Fusion Protein with Potential to Modulate the PD-1 PathwaySolomon Langermann, Ph.D., CSO, Amplimmune

Emerging Targets

Cytokine Fusions for Cancer ImmunotherapyCatherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland

Mechanism of Action and Progress Update for MGA271 Targeting B7-H3 for Solid TumorsPaul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics

CDX-1127: An Agonist Anti-CD27 Monoclonal Antibody (mAb) that Activates CD27 Expressing T Cells in the Context of T Cell Receptor StimulationLawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc.

ARGX-110: A Potently Neutralizing, Humanized Monoclonal Antibody to CD70 with Enhanced ADCC PropertiesAlain Thibault, M.D., CMO arGEN-X BV, The Netherlands

Targeting CD47-SIRPa Interactions for Potentiating Antibody Therapy Against Cancer Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin, The Netherlands

Clinical Development of Immunomodulatory Antibodies

Clinical Trials Design for Cancer ImmunotherapeuticsHarriet Kluger M.D., Associate Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program, Yale Cancer Center

Characteristics and Management of Immune-Related Adverse Effects Associated with Ipilimumab, a New Immunotherapy for Metastatic MelanomaStephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer Center

Bispecific Immunomodulatory Antibodies

Safety Challenges to Development of Immune System Activating AntibodiesRakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Pathology & LAR, Medimmune

MCLA-117: A Biclonics – ENGAGE Bispecific IgG Product Lead Targeting CLEC12A and CD3 in AMLLex Bakker, Ph.D., Chief Development Officer, Merus, The Netherlands

Bispecific Antibody Targeting CD47 Aiming at Increasing Phagocytosis of Cancer CellsKrzysztof Masternak, Ph.D., Head, Biology, Novimmune SA, Switzerland

5 ImmunotherapiesCongress.com

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post-show delegate lists. Customizable sponsorship packages allow you to achieve your objectives before, during, and long after the event. Signing on early will allow you to maximize exposure to hard-to-reach decision makers!

Agenda PresentationsShowcase your solutions to a guaranteed, highly-targeted audience. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding, and access to cooperative marketing efforts by CHI.

Breakfast & Luncheon PresentationsOpportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-only VIP Dinner/Hospitality SuiteSponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor’s objectives:

• Purely social• Focus group• Reception style • Plated dinner with specific conversation focus

ExhibitExhibitors will enjoy facilitated networking opportunities with high-level conference delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

*Inquire about additional branding opportunities!

LOOKING FOR ADDITIONAL wAYS TO DRIVE LEADS TO YOUR SALES TEAM? CHI CAN HELP!

we offer clients numerous options for custom lead generation programs to address their marketing and sales needs, including:

Custom Lead Generation Programs: • Targeted campaign promotion to unparalleled database of

800,000+ individuals in the life sciences• Experienced marketing team promotes campaign, increasing

awareness and leads

Live Webinars:• Assistance in procuring speakers• Experienced moderators• Dedicated operations team to coordinate all efforts

White Papers:• Industry recognized authors, with vast editorial experience, available

to help write your white paper

CHI also offers market surveys, podcasts, and more!

To customize your participation at this event, please contact:Suzanne Carroll – Senior Business Development Manager781-972-5452 | scarroll@healthtech.com

SPONSORSHIP, EXHIBIT, AND LEAD GENERATION OPPORTUNITIES

Co-Located Event

August 13-15, 2013 • Hilton Boston Back Bay Hotel • Boston, MA

August 14-15

Eighth Annual

Novel Vaccines: Innovations & Adjuvants To Advance the Science of Vaccines

AdditionAl registrAtion detAilsEach registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.to view our substitutions/Cancellations Policy, go to http://www.healthtech.com/regdetailsVideo and or audio recording of any kind is prohibited onsite at all CHI events.

Receive a FREE eNewsletter by signing up at chimediagroup.com

The latest industry news, commentary and highlights from Bio-IT World

Innovative management in clinical trials

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets.For a detailed list of reports, visit InsightPharmaReports.com, or contact Rose LaRaia, rlaraia@healthtech.com, +1-781-972-5444.

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit barnettinternational.com.

Cambridge Healthtech Associates™ (CHA™) leverages its extensive network and unique collaborative model in consulting, technology evaluations and community-based communication services to help clients in the life sciences industry commercialize and penetrate the marketplace to increase revenue. Visit www.chacorporate.com.

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 • www.healthtech.com • Fax: 781-972-5425

Pricing and registration informationshort Courses

Academic, government, (includes access to short courses only) Commercial hospital-affiliated

Single Short Course $699 $399Two Short Courses $999 $699

3 Day Pricing • august 13-15

(excludes short courses)

PACkAge A - Novel Vaccines: Innovations & Adjuvants

Early Registration Deadline until May 17, 2013 $2049 $1025Advance Registration Deadline until July 19, 2013 $2199 $1099Registrations after July 19, 2013 and on-site $2399 $1149

PACkAge B - Emerging Cancer Immunotherapies and Vaccines + Immunomodulatory Antibodies for Cancer

Early Registration Deadline until May 17, 2013 $2049 $1025Advance Registration Deadline until July 19, 2013 $2199 $1099Registrations after July 19, 2013 and on-site $2399 $1149

1.5 Day Pricing

(excludes short courses)

PACkAge A - Emerging Cancer Immunotherapies and Vaccines • August 13-14

Early Registration Deadline until May 17, 2013 $1399 $649Advance Registration Deadline until July 19, 2013 $1599 $729Registrations after July 19, 2013 and on-site $1799 $799

PACkAge B - Immunomodulatory Antibodies for Cancer • August 14-15

Early Registration Deadline until May 17, 2013 $1399 $649Advance Registration Deadline until July 19, 2013 $1599 $729Registrations after July 19, 2013 and on-site $1799 $799

ConferenCe disCounts

Poster submission-Discount ($50 Off)Poster abstracts are due by July 19, 2013. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. *CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

Alumni discount-Discount (SAVE 20%) Cambridge Healthtech Institute (CHI) appreciates your past participation at the ImVacS & the Immunotherapies Congress. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

register 3 - 4th is free: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

If you are unable to attend but would like to purchase the ImVacS & the Immunotherapies Congress CD for $750 (plus shipping), please visit ImVacS.com. Massachusetts delivery will include sales tax.

How to Register: ImmunotherapiesCongress.comreg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode iMt P

when registering!

(Alumni and Register 3 - 4th is free discounts cannot be combined)

ImmunoThe

Congressherapies

August 13-15, 2013Boston, MA